NasdaqGS:VRTXBiotechs
Maze Therapeutics Adds Pressure To Vertex In APOL1 Kidney Disease Race
Maze Therapeutics reported promising Phase II results for its APOL1-mediated kidney disease candidate MZE829.
The company plans to move MZE829 into pivotal testing, targeting the same indication as Vertex Pharmaceuticals' inaxaplin program.
This development introduces a new competitor to NasdaqGS:VRTX in the APOL1-mediated kidney disease space.
Vertex Pharmaceuticals, listed as NasdaqGS:VRTX, is known for its focus on serious diseases with high unmet need, and inaxaplin is one of its key...